Seres Therapeutics (MCRB) Gains from Investment Securities (2015 - 2024)
Seres Therapeutics (MCRB) posted Gains from Investment Securities of -$130000.0 for Q2 2024, up 68.75% sequentially from -$416000.0 in Q1 2024, and up 1.52% YoY from -$128059.7 in Q3 2023.
Seres Therapeutics (MCRB) Gains from Investment Securities (2015 - 2024) Analysis & Trends
Seres Therapeutics has reported Gains from Investment Securities for 3 years, with the latest figure at -$130000.0 in Q2 2024.
- Quarterly Gains from Investment Securities rose 1.52% year-over-year to -$130000.0 in Q2 2024, while the trailing twelve-month figure through Mar 2025 was -$130000.0 (up 93.4% YoY) and the FY2024 annual result came in at -$546000.0, up 64.86% from the prior year.
- Gains from Investment Securities advanced to -$130000.0 in Q2 2024 per MCRB's latest filing, from -$416000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at -$130000.0 in Q2 2024 and troughed at -$1.0 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -130,000.00 |
| Jun 30, 2024 | -130,000.00 |
| Mar 31, 2024 | -416,000.00 |
| Mar 31, 2024 | -416,000.00 |
| Dec 31, 2023 | -410,000.00 |
| Dec 31, 2023 | -410,000.00 |
| Sep 30, 2023 | -1.01 Mn |
| Sep 30, 2023 | -1.01 Mn |
| Jun 30, 2023 | -132,000.00 |
| Jun 30, 2023 | -132,000.00 |
| Jun 30, 2015 | 220,000.00 |
| Jun 30, 2015 | 220,000.00 |
| Mar 31, 2015 | -213,000.00 |
| Mar 31, 2015 | -213,000.00 |